Showing 5831-5840 of 7383 results for "".
- AAD Launches Campaign to Support Skin Self Examshttps://practicaldermatology.com/news/aad-launches-campaign-to-support-skin-self-exams/2457782/In recognition of Skin Cancer Awareness Month in May and Melanoma Monday® on May 7, the American Academy of Dermatology is encouraging the public to be a “Skin Can
- Sensus Appoints Rita Gable as VP of Sales, Oncologyhttps://practicaldermatology.com/news/sensus-appoints-rita-gable-as-vp-of-sales-oncology/2457783/Sensus Healthcare, Inc. has appointed Rita Gable as Vice President of Sales – Oncology. Ms. Gable, who will report to Joe Sardano, Sensus CEO, has 15 years of sales e
- FDA Agrees to Priority Review of Cemiplimab for Advanced Squamous Cell Carcinomahttps://practicaldermatology.com/news/fda-agrees-to-priority-review-of-cemiplimab-for-advanced-squamous-cell-carcinoma/2457785/The FDA has accepted the Biologics License Application (BLA) for cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC w
- Encore Dermatology Launches Impoyz Cream 0.025%, a Newly Formulated High-Potency Topical Corticosteroidhttps://practicaldermatology.com/news/encore-dermatology-launches-impoyz-cream-0025-a-newly-formulated-high-potency-topical-corticosteroid/2457787/Encore Dermatology Inc. launched its new topical product, Impoyz Cream, indicated for the treatment of moderate to severe plaque psoriasis in patients 18 years of age or older. Impoyz Cream is the only FDA-approved high-potency topical corticosteroid with 0.025% clobetasol propionate. &ld
- New Phase 4 Data: Epiduo Forte Gel Decreased Acne Lesions, Reduced Risk of Scarshttps://practicaldermatology.com/news/new-phase-4-data-epiduo-forte-gel-decreased-acne-lesions-reduced-risk-of-scars/2457788/Results from OSCAR, a Phase 4, multicenter, randomized, investigator-blinded, vehicle-controlled, intra-individual comparison study (right/left half-face), revealed that Epiduo Forte (adapalene and benzoyl peroxide) Gel 0.3%/2.5% not only decreased acne lesions, as measured over a period of
- Acne Survey at Twins Convention Affirms Genetic Linkhttps://practicaldermatology.com/news/acne-survey-at-twins-convention-affirms-genetic-link/2457789/A survey of identical and fraternal twin pairs at the Twins Days Festival in Twinsburg, OH, and published in the April issue of the Journal of Drugs in Dermatology, shows acne may be primarily caused by genetics.
- Parents Just Don't Understand Risks of Sun Exposure in Springhttps://practicaldermatology.com/news/parents-just-dont-understand-risks-of-sun-exposure-in-spring/2457791/Slightly more than 90 percent of parents underestimate the sun’s strength in spring and as a result, don’t adequately protect their children, according to a survey by parent magazine Kinderzeit.org. Specifically, 90.6 percent of parents polled tend to forget to apply sun
- First Androgenetic Alopecia Patient Dosed in a Pilot Study with Aclaris' ATI-502 Topicalhttps://practicaldermatology.com/news/first-androgenetic-alopecia-patient-dosed-in-a-pilot-study-with-aclaris-ati-502-topical/2457795/Aclaris Therapeutics, Inc. initiated a Phase 2 open-label study of ATI-502, a topical Janus Kinase (JAK) 1/3 inhibitor (ATI-502 Topical), in patients with androgenetic alopecia (AGA), a condition characterized by a genetically determined male/female-pattern baldness. This trial will
- Saudi Arabia Welcomes Scalisi Skin Carehttps://practicaldermatology.com/news/saudi-arabia-welcomes-scalisi-skin-care/2457799/Select doctors’ offices and medical clinics across Saudi Arabia now carry the Scalisi collection. This adds to their existing distribution in spas and medispas in the US, Wynn and Encore Resorts in both Las Vegas, and Macau, China, and online on QVC.com, Amazon.com, and
- Cutera: 20 Years, 20 Productshttps://practicaldermatology.com/news/cutera-20-years-20-products/2457802/Cutera, Inc. is celebrating 20 years of best-in-class product innovation with continued commitment to the industry and its providers, marking the milestone at the Annual Meeting of the American Society for Laser Medicine and Surgery in Dallas. In conjunction with the 20